Doç.Dr. Burçin Çakan Demirel

Hakkında

Burçin Çakan Demirel, Tıbbi Onkoloji alanında Medipol Mega Üniversite Hastanesi doktor kadrosunda yer almaktadır.

Eğitim ve deneyim

Eğitim

• 2023
• Pamukkale Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji
• 2018
• İstanbul Medipol Üniversitesi Tıp Fakültesi, İç Hastalıkları
• 2013
• Adnan Menderes Üniversitesi, Tıp Fakültesi

Deneyim

• 2023 - 2025
• Bağcılar Eğitim ve Araştırma Hastanesi
• Uzm.Dr.
• 2019 - 2019
• Amasya Taşova Devlet Hastanesi
• Elazığ Fethi Sekin Şehir Hastanesi

Bilimsel yayınlar

• 7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)
• Çakan B, Açikgöz O, Bilici A, Demir T, Oven BB, Hamdard J, Olmuşçelik O, Ölmez OF, Şeker M, Yıldız Ö. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. JBUON. 2021;26(5):1908-1917.
• Goktas Aydin S, Cakan Demirel B, Bilici A, et al. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer. Curr Med Res Opin. 2022;38(10):1751-1758. doi:10.1080/03007995.2022.2108619
• Demiray AG, Yaren A, Sungurtekin U, Baltalarli PB, Demirkan N, Herek D, Yapar Taskoylu B, Gokoz Dogu G, Degirmencioglu S, Ozgen U, Saginc H, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. The effect of continuing chemotherapy after chemoradiotherapy during the time to surgery on tumor response and survival for local advanced rectal cancer. J Oncol. 2022;2022:4108677. doi:10.1155/2022/4108677
• Acikgoz O, Cakan B, Demir T, et al. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer. Medicine (Baltimore). 2021;100(44):e27712. doi:10.1097/MD.0000000000027712
• Demiray AG, Demiray A, Yaren A, Yapar Taskoylu B, Gokoz Dogu G, Degirmencioglu S, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. Evaluation of serum microRNA Let-7c and Let-7d as predictive biomarkers for metastatic pancreatic cancer. Turk J Gastroenterol. 2022;33(3):257–263. doi:10.5152/tjg.2022.21829
• Karan C, Yaren A, Demirel BC, et al. Pretreatment PLR is preferable to NLR and LMR as a predictor in locally advanced and metastatic bladder cancer. Cancer Diagn Progn. 2023;3(6):706-715. doi:10.21873/cdp.10275
• Kınıkoğlu O, Odabaş H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, et al. Combining endocrine therapy with trastuzumab emtansine improves progression-free survival and overall survival in HER2-positive, hormone receptor-positive metastatic breast cancer. Medicina. 2024;60(6):951. doi:10.3390/medicina60060951
• Kahraman S, Erul E, Gumusay O, Guven DC, Aksoy S, Basaran G, Seyyar M, Sahin E, Cabuk D, Bayram E, Paydas S, Cakan Demirel B, et al. Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study. BMC Cancer. 2024;24(1):726. doi:10.1186/s12885-024-12347-3
• Kahraman S, Erul E, Gumusay O, Guven DC, Aksoy S, Basaran G, Yaren A, Cakan Demirel B, et al. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age subgroups: Turkish Oncology Group (TOG) retrospective study. BMC Cancer. 2024;24(1):1275. doi:10.1186/s12885-024-12775-0
• 7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler
• Goktas Aydin S, Aydin A, Cakan Demirel B, Demir O, Bayramgil A, Kutlu O, Yildirim C, Aksoy A, Gulturk I, Taskaynatan H, Senocak Tasci E, Koseoglu C. A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy. J Clin Oncol. 2025;43(16_suppl):12033. doi:10.1200/JCO.2025.43.16_suppl.12033
• CD4/6 İnhibitörü Kullanan Metastatik Hormon Pozitif Her2 Negatif Meme Kanserli Hastalarda Conut Skorunun Sağkalıma Etkisi AMORE-2022
• Metastatik Safra Yolları Ve Safra Kesesi Kanserli Hastalarda Tedavi Öncesi Mutlak Lenfosit, Albumin, Hemoglobin, C-Reaktif Protein Ve Ldh Düzeylerinin Sağkalım Üzerine Etkisi Tek Merkez Deneyimi -TTOK 2022
• 7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler
• 7.5. Ulusal hakemli dergilerde yayınlanan makaleler ve bildiri kitabında basılan bildiriler
• Yapar Taşköylü B, Avcı E, Demiray AG, Değirmencioğlu S, Gököz Doğu G, Yaren A, Ergin A, Kılıç D, Karan C, Çakan Demirel B, Doğan T, Özdemir M. Relationship between neutrophil/lymphocyte, platelet/lymphocyte, CRP/albumin ratio and survival in ovarian cancer. Pamukkale Medical Journal. 2021;14(3):763-769. doi:10.31362/patd.907695
• Demiray AG, Yaren A, Yapar Taskoylu B, Degirmencioglu S, Gokoz Dogu G, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. Should vitamin D level be measured before denosumab in patients with castration-resistant metastatic prostate cancer to prevent hypocalcemia? EJMI. 2021;5(3):313–316. doi:10.14744/ejmi.2021.48218
• Göktaş Aydın S, Çakan Demirel B, Bilici A, Yılmaz C, Topçu A, Aykan MB, Kahraman S, Atcı MM, Akbıyık I, Akgül F, Ölmez ÖF, Aydın A. The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors (Metastatik safra yolu kanseri olan yaşlı hastalarda optimal tedavi yaklaşımları ve prognostik faktörler). Acta Oncologica Turcica. 2023;56:81-89. doi:10.5505/aot.2023.03708
• Yapar Taskoylu B, Gokoz Dogu G, Cakan Demirel B, Sari T, Demiray AG, Degirmencioglu S, Yaren A, Ergin A, Avci E, Karan C, Dogan T, Ozdemir M. Evaluation of clinical, laboratory and treatment findings of oncology patients diagnosed with COVID-19 infection. EJMI. 2021;5(4):417–421. doi:10.14744/ejmi.2021.27607
• Cakan Demirel B, Yaren A, Demiray AG, Yapar Taşköylü B, Doğan T, Özdemir M, Güçlü Kantar T, Karan C, Değirmencioğlu S, Gököz Doğu G. Prognostic significance of systemic immune inflammation indices and prognostic nutritional index before CDK4/6 inhibitor therapy in hormone receptor–positive, HER2–negative metastatic breast cancer patients. Pamukkale Med J. 2023;16(4):682-695. doi:10.31362/patd.1268419
• Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Demiray AG, Degirmencioglu S, Yaren A, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. Prognostic value of a new marker, IBI score and NLR change in non-small cell lung cancer patients receiving immune checkpoint inhibitors (Prognostic value of IBI score and NLR change in NSCLC). Med J Mugla Sitki Kocman Univ. 2025;12(2):91-98. doi:10.47572/muskutd.1603917
• Yapar Taskoylu B, Bir F, Demiray AG, Degirmencioglu S, Gokoz Dogu G, Yaren A, Ergin A, Karan C, Cakan Demirel B, Dogan T, Ozdemir M, Guclu Kantar T. The association of mismatch-repair (MMR) deficiency with tumor infiltrating lymphocytes and survival in patients with ovarian cancer. EJMA. 2024;4(1):22–27. doi:10.14744/ejma.2023.74946
• Dogan T, Yaren A, Demiray AG, Yapar Taskoylu B, Cakan Demirel B, Ozdemir M, Guclu Kantar T, Degirmencioglu S, Gokoz Dogu G. The effect of pre-treatment inflammatory response markers on survival in locally advanced unresectable and metastatic gastric cancer: a retrospective cross-sectional study. Pamukkale Med J. 2024;17(2):XXX–XXX. doi:10.31362/patd.1265291
• Kahraman S, Hizal M, Gumusay O, Basaran G, Seyyar M, Sahin E, Cabuk D, Yasar A, Bayoglu IV, Bayram E, Paydas S, Gulbagci B, Hacibekiroglu I, Cakan Demirel B, et al. HER2-low expression in patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy. Turk J Clin Lab. 2024;15(2):255–262. doi:10.18663/tjcl.1639022
• Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Demiray AG, Degirmencioglu S, Yaren A, Arslan M, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. Use of albumin and CRP-related immuno-nutritional markers for prediction of locoregional response to treatment in unresectable hepatocellular carcinoma. Pamukkale Med J. 2025;18(1):87–97. doi:10.31362/patd.1471860
• Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Yaren A, Degirmencioglu S, Demiray AG, Erdemir A, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy. Pamukkale Med J. 2025;18(4):733–747. doi:10.31362/patd.1598359
• 7.7. Diğer yayınlar
• Cakan Demirel B. Febril kanser hastasında ampirik antibiyotik tedavisi. In: Soylu HM, Sedef AM, eds. Kanser ve Enfeksiyon. Ankara: Akademisyen Kitabevi; 2023:117–126. doi:10.37609/akya.2853. ISBN 9786253994051.
• Cakan Demirel B. Kanser hastasında atriyal fibrilasyon. In: Baysal E, Okşul M, Şener YZ, eds. Atriyal Fibrilasyon Tanı ve Tedavisine Güncel Yaklaşım. Ankara: Akademisyen Kitabevi; 2023:197–206.
• Cakan Demirel B. Kanser tedavisi ilişkili hipertansiyon ve tedavisi. In: Dilmen Y, ed. Hipertansiyon Tanı ve Tedavisine Güncel Yaklaşım. Ankara: Akademisyen Kitabevi; 2023:311–321. doi:10.37609/akya.607. ISBN 9786257496025.

Çalışma yerleri 1